乌帕替尼（Upadacitinib）15mg
1. Composition:
Upadacitinib is a selective Janus kinase (JAK) inhibitor, with its main component being upadacitinib. It is an oral small molecule drug specifically designed to inhibit the activity of JAK-1 and is classified as a targeted therapy.
2. Pharmacodynamics and Indications:
Upadacitinib is used to treat moderate to severe active rheumatoid arthritis (RA), psoriatic arthritis, atopic dermatitis, and ulcerative colitis, among other immune-mediated chronic inflammatory diseases. It reduces inflammatory responses by inhibiting the JAK-1 signaling pathway, alleviating joint pain and inflammatory symptoms in patients, and slowing the progression of joint damage.
3. Usage Instructions:
Upadacitinib is usually administered orally in tablet form, with the dosage varying based on the patient's condition and the doctor's recommendations. Typically, rheumatoid arthritis patients take 15 mg daily, while ulcerative colitis patients may adjust their dosage to 30 mg. It is recommended to take it at the same time each day and can be taken with or without food.
4. Research and Development History:
Upadacitinib was developed by AbbVie. AbbVie has extensive research experience in the field of JAK inhibitors, and upadacitinib is one of the most selective JAK-1 inhibitors identified during the development process. In 2019, the FDA approved upadacitinib for the treatment of rheumatoid arthritis, and it has since received further approvals for other indications.
5. Mechanism of Action:
Upadacitinib interferes with the Janus kinase signaling pathway by inhibiting the activity of JAK-1, which plays a crucial role in many inflammatory diseases. Specifically, the JAK signaling pathway regulates the inflammatory response of the immune system by mediating cytokine signaling. The selective inhibition of JAK-1 by upadacitinib effectively reduces the production of various pro-inflammatory cytokines, thereby decreasing chronic inflammation and improving symptoms.
6. Summary:
- Drug Name: Upadacitinib
- Drug Category: JAK-1 inhibitor
- Indications:Rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, etc.
- Mechanism of Action: Inhibits the JAK-1 pathway, reducing inflammatory responses
- Common Dosage: Taken orally once daily, dosage depends on the condition
